430 related articles for article (PubMed ID: 20730629)
1. Pathology and current treatment of neurodegenerative sphingolipidoses.
Eckhardt M
Neuromolecular Med; 2010 Dec; 12(4):362-82. PubMed ID: 20730629
[TBL] [Abstract][Full Text] [Related]
2. Recent advances and novel treatments for sphingolipidoses.
Arenz C
Future Med Chem; 2017 Sep; 9(14):1687-1700. PubMed ID: 28857617
[TBL] [Abstract][Full Text] [Related]
3. Genetic defects in the sphingolipid degradation pathway and their effects on microglia in neurodegenerative disease.
Allende ML; Zhu H; Kono M; Hoachlander-Hobby LE; Huso VL; Proia RL
Cell Signal; 2021 Feb; 78():109879. PubMed ID: 33296739
[TBL] [Abstract][Full Text] [Related]
4. Sphingolipids and neuronal degeneration in lysosomal storage disorders.
Grassi S; Chiricozzi E; Mauri L; Sonnino S; Prinetti A
J Neurochem; 2019 Mar; 148(5):600-611. PubMed ID: 29959861
[TBL] [Abstract][Full Text] [Related]
5. Characterization of
Sellin J; Schulze H; Paradis M; Gosejacob D; Papan C; Shevchenko A; Psathaki OE; Paululat A; Thielisch M; Sandhoff K; Hoch M
Dis Model Mech; 2017 Jun; 10(6):737-750. PubMed ID: 28389479
[TBL] [Abstract][Full Text] [Related]
6. My journey into the world of sphingolipids and sphingolipidoses.
Sandhoff K
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(10):554-82. PubMed ID: 23229750
[TBL] [Abstract][Full Text] [Related]
7. Neuronal sphingolipidoses: Membrane lipids and sphingolipid activator proteins regulate lysosomal sphingolipid catabolism.
Sandhoff K
Biochimie; 2016 Nov; 130():146-151. PubMed ID: 27157270
[TBL] [Abstract][Full Text] [Related]
8. A view on sphingolipids and disease.
Kolter T
Chem Phys Lipids; 2011 Sep; 164(6):590-606. PubMed ID: 21570958
[TBL] [Abstract][Full Text] [Related]
9. A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders.
Pastores GM; Sathe S
Drugs R D; 2006; 7(6):339-48. PubMed ID: 17073517
[TBL] [Abstract][Full Text] [Related]
10. Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention.
Aerts JM; Hollak C; Boot R; Groener A
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):905-14. PubMed ID: 12803924
[TBL] [Abstract][Full Text] [Related]
11. Sphingolipids and cell signalling.
Fredman P
J Inherit Metab Dis; 1998 Aug; 21(5):472-80. PubMed ID: 9728328
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in therapeutic approaches for lysosomal storage diseases.
Urbanelli L; Magini A; Polchi A; Polidoro M; Emiliani C
Recent Pat CNS Drug Discov; 2011 Jan; 6(1):1-19. PubMed ID: 21073432
[TBL] [Abstract][Full Text] [Related]
13. Molecular facets of sphingolipids: mediators of diseases.
Ozbayraktar FB; Ulgen KO
Biotechnol J; 2009 Jul; 4(7):1028-41. PubMed ID: 19579220
[TBL] [Abstract][Full Text] [Related]
14. [Sphingolipid storage diseases of the central nervous system: bases of biochemical and clinical heterogeneity].
Sandhoff K; Quintern L
Naturwissenschaften; 1988 Mar; 75(3):123-31. PubMed ID: 3132618
[TBL] [Abstract][Full Text] [Related]
15. The expanding boundaries of sphingolipid lysosomal storage diseases; insights from Niemann-Pick disease type C.
Platt FM
Biochem Soc Trans; 2023 Oct; 51(5):1777-1787. PubMed ID: 37844193
[TBL] [Abstract][Full Text] [Related]
16. The role of brain innate immune response in lysosomal storage disorders: fundamental process or evolutionary side effect?
Vitner EB
FEBS Lett; 2020 Nov; 594(22):3619-3631. PubMed ID: 33131047
[TBL] [Abstract][Full Text] [Related]
17. How membrane dysfunction influences neuronal survival pathways in sphingolipid storage disorders.
Sural-Fehr T; Bongarzone ER
J Neurosci Res; 2016 Nov; 94(11):1042-8. PubMed ID: 27638590
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the biochemistry and genetics of sphingolipidoses.
Ozkara HA
Brain Dev; 2004 Dec; 26(8):497-505. PubMed ID: 15533650
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory response and its relation to sphingolipid metabolism proteins: Chaperones as potential indirect anti-inflammatory agents.
Yagci ZB; Esvap E; Ozkara HA; Ulgen KO; Olmez EO
Adv Protein Chem Struct Biol; 2019; 114():153-219. PubMed ID: 30635081
[TBL] [Abstract][Full Text] [Related]
20. Finding pathogenic commonalities between Niemann-Pick type C and other lysosomal storage disorders: Opportunities for shared therapeutic interventions.
Yañez MJ; Marín T; Balboa E; Klein AD; Alvarez AR; Zanlungo S
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165875. PubMed ID: 32522631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
